The aim of this study was to investigate the prevalence, characteristics, and clinical outcomes of metastatic NSCLC harboring uncommon EGFR mutation, to compare treatment efficacy in patients with this condition between EGFR-tyrosine kinase inhibitor (EGFR-TKI) and chemotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.